AUS
NZ
UK
CA
USA
IND
Highlights:
-
Jasper Therapeutics announced promising results from its SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab for chronic inducible urticaria (CIndU).
-
A clinical response was observed in 93% of participants within six weeks, with 83% of those in the 120mg dose cohort achieving a complete response.
-
No serious adverse events were reported, and significant reductions in tryptase levels correlated with clinical responses.
Description:
Jasper Therapeutics {NASDAQ:JSPR} has reported encouraging findings from its SPOTLIGHT Phase 1b/2a clinical trial evaluating subcutaneous briquilimab in adults suffering from chronic inducible urticaria (CIndU). This condition is characterized by recurrent hives triggered by specific stimuli, leading to discomfort and reduced quality of life for affected individuals.
The trial's results indicate that 14 out of 15 participants, representing 93%, achieved a clinical response within six weeks of treatment. Notably, among those receiving the 120mg dose, 10 out of 12 participants, or 83%, experienced a complete response, highlighting the potential effectiveness of briquilimab for this patient population. Importantly, the trial reported no serious adverse events or any grade 3+ adverse events, suggesting a favorable safety profile for the treatment.
Additionally, significant reductions in tryptase levels were observed, correlating with the clinical responses seen in participants. Tryptase is an enzyme associated with mast cell activation, which plays a key role in allergic reactions, making its reduction an important indicator of treatment efficacy.
In light of these positive outcomes, Jasper Therapeutics plans to enroll participants in a 180mg dose cohort to further explore the drug's efficacy and safety. The company also anticipates presenting full data from the SPOTLIGHT study in the first half of 2025.
Furthermore, Jasper is set to report initial data from all cohorts of the BEACON study focusing on chronic spontaneous urticaria during the week of January 6th, 2025. These developments indicate Jasper Therapeutics' commitment to advancing its pipeline and addressing unmet needs in the treatment of urticaria.
